N. prodotti: 0
Totale ordine: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
Online ISSN 1827-1936
ADVANCES IN RADIOIMMUNOIMAGING AND RADIOIMMUNOTHERAPY
Renard V. 1, Staelens L. 2, Signore A. 3, 4, Van Belle S. 1, Dierckx R. A. 4, Van De Wiele C. 5
1 Department of Medical Oncology Ghent University Hospital, Ghent, Belgium
2 Department of Radiopharmacy University of Ghent, Ghent, Belgium
3 Department of Nuclear Medicine La Sapienza University of Rome, Rome, Italy
4 Department of Nuclear Medicine and Molecular Imaging Groningen University Medical Center University of Groningen, Groningen, The Netherlands
5 Department of Nuclear Medicine Ghent University Hospital, Ghent, Belgium
Aim. This pilot study reports on the uptake of 123I-interleukin 2 (IL-2) in metastatic renal cell carcinoma (MRCC) patients and its relationship to prognostic factors of response or failure of MRCC to cytokines treatment.
Methods. Nine consecutive patients with MRCC underwent an 123I-IL-2 scan (6 male and 3 female; mean age 64 years; range 51-78). Uptake in metastases was related to a summed score of 4 independent factors, predictive of rapid progression under cytokine treatment as defined by Negrier et al.
Results. Four patients presented with metastases at one site, 4 at 2 sites and one patient at 3 different sites. Summed scores were: 5 patients had a summed score of 1; 3 a summed score of 2 and 1 patient a summed score of 3. Uptake of 123I-IL-2 by tumor tissue was found in only 2 patients. Uptake occurred in 1 patient with a summed score of 3 and in 1 with a summed score of 2.
Conclusion. In this small series of patients with MRCC, 123I-IL-2 uptake was found in tumors of 2 patients who less likely will benefit from cytokine treatment. Additional studies are needed to assess the relationship between the pretreatment uptake of 123I-IL2 in MRCC and the response to IL-2 therapy.